Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.

Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.

Sandhoff disease is a severe neurodegenerative glycosphingolipid (GSL) lysosomal storage disorder, currently without treatment options. One therapeutic approach under investigation is substrate reduction therapy (SRT). By partially inhibiting GSL biosynthesis, the impaired rate of GSL catabolism is...

Description complète

Détails bibliographiques
Auteurs principaux:	Andersson, U, Smith, D, Jeyakumar, M, Butters, T, Borja, M, Dwek, R, Platt, F
Format:	Journal article
Langue:	English
Publié:	2004

Documents similaires

Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease
par: Ulrika Andersson, et autres
Publié: (2004-08-01)

NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
par: Jeyakumar, M, et autres
Publié: (2004)

N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
par: Andersson, U, et autres
Publié: (2000)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice
par: Baek, R, et autres
Publié: (2004)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
par: Baek, R, et autres
Publié: (2008)

Substrate reduction therapy in mouse models of the glycosphingolipidoses.
par: Platt, F, et autres
Publié: (2003)

Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation.
par: Jeyakumar, M, et autres
Publié: (2001)

N-butyldeoxygalactonojirimycin reduces postnatal cerebellar ganglioside content in a mouse model of GM1 gangliosidosis
par: Kasperzyk, J, et autres
Publié: (2004)

N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
par: Kasperzyk, J, et autres
Publié: (2004)

Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice
par: Baek, R, et autres
Publié: (2005)

MRS reveals additional hexose N-acetyl resonances in the brain of a mouse model for Sandhoff disease.
par: Lowe, J, et autres
Publié: (2005)

Substrate reduction therapy in Sandhoff disease: Evidence for improvement in nervous function in patients treated with miglustat
par: Lachmann, R, et autres
Publié: (2006)

Analysis of stored oligosaccharides in a mouse model of a glycolipid storage (Sandhoff) disease
par: Awan, F, et autres
Publié: (2003)

Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.
par: Elliot-Smith, E, et autres
Publié: (2008)

Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.
par: Pelled, D, et autres
Publié: (2003)

Beneficial effects of acetyl-DL-Leucine (ADLL) in a mouse model of Sandhoff disease
par: Kaya, E, et autres
Publié: (2020)

New developments in treating glycosphingolipid storage diseases.
par: Platt, F, et autres
Publié: (2005)

Substrate reduction therapy
par: Platt, F, et autres
Publié: (2007)

Substrate reduction therapy.
par: Platt, F, et autres
Publié: (2008)

Design, synthesis, and biological evaluation of enantiomeric beta-N-acetylhexosaminidase inhibitors LABNAc and DABNAc as potential agents against Tay-Sachs and Sandhoff disease.
par: Rountree, J, et autres
Publié: (2009)

Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
par: Denny, C, et autres
Publié: (2010)

Infantile Sandhoff's disease
par: K Sass, et autres
Publié: (2009-08-01)

Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
par: Jeyakumar, M, et autres
Publié: (2002)

Storage solutions: treating lysosomal disorders of the brain.
par: Jeyakumar, M, et autres
Publié: (2005)

An inducible mouse model of late onset Tay-Sachs disease.
par: Jeyakumar, M, et autres
Publié: (2002)

Circadian profiling in two mouse models of lysosomal storage disorders; Niemann Pick type-C and Sandhoff disease.
par: Richardson, K, et autres
Publié: (2016)

Efficacy of a Bicistronic Vector for Correction of Sandhoff Disease in a Mouse Model
par: Evan Woodley, et autres
Publié: (2019-03-01)

Dysregulation of the NLRP3 Inflammasome and Promotion of Disease by IL-1β in a Murine Model of Sandhoff Disease
par: Nick Platt, et autres
Publié: (2025-01-01)

Glycosphingolipid storage leads to the enhanced degradation of the B cell receptor in Sandhoff disease mice.
par: te Vruchte, D, et autres
Publié: (2010)

An Inducible Mouse Model of Late Onset Tay–Sachs Disease
par: Mylvaganam Jeyakumar, et autres
Publié: (2002-08-01)

Inhibition of glycogen breakdown by imino sugars in vitro and in vivo.
par: Andersson, U, et autres
Publié: (2004)

Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.
par: Platt, F, et autres
Publié: (2001)

Pharmacological impairment of acrosome formation and sperm head morphogenesis reveals essential role of glycosphingolipids in spermiogenesis
par: van der Spoel, A, et autres
Publié: (2002)

Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease.
par: Karen M Ashe, et autres
Publié: (2011-01-01)

Decrease in Myelin-Associated Lipids Precedes Neuronal Loss and Glial Activation in the CNS of the Sandhoff Mouse as Determined by Metabolomics
par: Emmanuelle Lecommandeur, et autres
Publié: (2020-12-01)

Membrane disruption and cytotoxicity of hydrophobic N-alkylated imino sugars is independent of the inhibition of protein and lipid glycosylation.
par: Mellor, H, et autres
Publié: (2003)

Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.
par: Jeyakumar, M, et autres
Publié: (2003)

Impaired neural differentiation of induced pluripotent stem cells generated from a mouse model of Sandhoff disease.
par: Yasuhiro Ogawa, et autres
Publié: (2013-01-01)

Abnormal differentiation of Sandhoff disease model mouse-derived multipotent stem cells toward a neural lineage.
par: Yasuhiro Ogawa, et autres
Publié: (2017-01-01)

Glycosphingolipid profiling of tissues from mouse models of human lysosomal storage disorders
par: Priestman, D, et autres
Publié: (2008)